Skip to main content
. 2016 Jan 28;48(3):1092–1101. doi: 10.4143/crt.2015.316

Fig. 1.

Fig. 1.

Progression-free survival (PFS) (A) and overall survival (OS) (B) curves for first-line systemic therapies in patients with metastatic renal cell carcinoma treated with immunotherapy alone, targeted therapy alone, or both therapies in sequence. ICTx, immunotherapy; TT, targeted therapy.